Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Aravive, Inc.VSAR · Entity 114535 | Director | December 20, 2017 | December 22, 2017 |
| HYPERION DEFI, INC.EYEN · Entity 7220 | Director | November 17, 2021 | November 22, 2021 |
| Zentalis Pharmaceuticals, Inc.ZNTL · Entity 5772 | Director · President & CEO | April 04, 2022 | April 05, 2022 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Aravive, Inc.
Report date December 20, 2017 · Filed December 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,880 |
Reported balance
After 2017-12-20 transaction · row 1
1 source rowRow 1 · 2017-12-20 · Grant · Acquired 11,200 · Balance 23,880 F1: Represents the grant of restricted stock units that vest 100% on December 20, 2018. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the grant of restricted stock units that vest 100% on December 20, 2018.
HYPERION DEFI, INC.
Report date November 17, 2021 · Filed November 22, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common Stock, par value $.0001SEC Table I · non-derivative | Direct | 26,322 |
Reported balance
After 2021-11-17 transaction · row 1
1 source rowRow 1 · 2021-11-17 · Grant · Acquired 6,963 · Balance 26,322 F1: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. |
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.59 · Expires 2031-11-17 | Direct | 9,653 |
Reported balance
After 2021-11-17 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2021-11-17 · Grant · Acquired 9,653 · Balance 9,653 F2: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted stock units that fully vest on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
F2: The option becomes exercisable on the earlier of November 17, 2022 or the date of the Issuer's 2022 annual meeting of stockholders, subject to the Reporting Person's continued service on the Issuer's Board of Directors and acceleration upon change in control.
Zentalis Pharmaceuticals, Inc.
Report date April 04, 2022 · Filed April 05, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,175,589 |
Ending reported balance
After 2022-04-05 transaction · row 3
3 source rows · reconciled sequenceRow 1 · 2022-04-04 · Sale · Disposed 10,471 · Balance 1,186,060 F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. Row 2 · 2022-04-05 · Sale · Disposed 7,971 · Balance 1,178,089 F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F2: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.84 to $51.83. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Row 3 · 2022-04-05 · Sale · Disposed 2,500 · Balance 1,175,589 F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F3: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.85 to $52.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Common StockSEC Table I · non-derivative | IndirectBy Spouse | 103,650 |
Reported balance
Holding disclosure · report date 2022-04-04 · row 4
Holding and transaction disclosures are not merged.
1 source rowRow 4 · Balance 103,650 |
| Common StockSEC Table I · non-derivative | IndirectBy Essex Group International, LLC | 974,302 |
Reported balance
Holding disclosure · report date 2022-04-04 · row 5
Holding and transaction disclosures are not merged.
1 source rowRow 5 · Balance 974,302 |
| Common StockSEC Table I · non-derivative | IndirectBy Hao Bao Zi Trust LLC | 213,600 |
Reported balance
Holding disclosure · report date 2022-04-04 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 213,600 F4: Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC except to the extent of his pecuniary interest therein, if any. |
| Common StockSEC Table I · non-derivative | IndirectBy Hao Jiao Zi Trust LLC | 125,000 |
Reported balance
Holding disclosure · report date 2022-04-04 · row 7
Holding and transaction disclosures are not merged.
1 source rowRow 7 · Balance 125,000 F5: Represents shares nominally held by Hao Jiao Zi Trust LLC on behalf of the Hao Jiao Zi Trust (the "Trust"), the sole member of Hao Jiao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Jiao Zi Trust LLC except to the extent of his pecuniary interest therein, if any. |
Filing footnotes · ownership attribution and instrument terms
F1: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021.
F2: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.84 to $51.83. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.85 to $52.70. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: Represents shares nominally held by Hao Bao Zi Trust LLC on behalf of the Hao Bao Zi Trust (the "Trust"), the sole member of Hao Bao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Bao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.
F5: Represents shares nominally held by Hao Jiao Zi Trust LLC on behalf of the Hao Jiao Zi Trust (the "Trust"), the sole member of Hao Jiao Zi Trust LLC. The Reporting Person's spouse is the investment adviser with sole power to make investment decisions regarding the securities held by the Trust. The Reporting Person disclaims beneficial ownership of the securities held by Hao Jiao Zi Trust LLC except to the extent of his pecuniary interest therein, if any.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| November 02, 2021 Filed Nov 2, 2021 23:24 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,494 | $79.40 | $118,623.75 |
DisclosureSEC source: 0001725160-21-000211 · wf-form4_163589546612485.xml · nonDerivative · entry 5 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,258,578 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $78.78 to $79.76. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 23:24 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 200 | $83.19 | $16,637.00 |
DisclosureSEC source: 0001725160-21-000211 · wf-form4_163589546612485.xml · nonDerivative · entry 4 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260,072 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $83.13 to $83.24. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 23:24 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,600 | $82.49 | $214,461.78 |
DisclosureSEC source: 0001725160-21-000211 · wf-form4_163589546612485.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,260,272 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $82.05 to $82.97. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 23:24 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 3,251 | $81.48 | $264,877.18 |
DisclosureSEC source: 0001725160-21-000211 · wf-form4_163589546612485.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,262,872 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $81.03 to $82.01. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| November 01, 2021 Filed Nov 2, 2021 23:24 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,420 | $80.72 | $356,795.66 |
DisclosureSEC source: 0001725160-21-000211 · wf-form4_163589546612485.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,266,123 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 21, 2021. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $80.03 to $81.02. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 01:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 27 | $67.15 | $1,813.05 |
DisclosureSEC source: 0001725160-21-000198 · wf-form4_163339651954978.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,270,543 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 01:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 16,308 | $66.58 | $1,085,757.29 |
DisclosureSEC source: 0001725160-21-000198 · wf-form4_163339651954978.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,270,570 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $66.15 to $67.09. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| October 04, 2021 Filed Oct 5, 2021 01:15 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 10,464 | $65.95 | $690,136.38 |
DisclosureSEC source: 0001725160-21-000198 · wf-form4_163339651954978.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,286,878 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $65.15 to $66.14. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 23:32 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 825 | $68.58 | $56,580.73 |
DisclosureSEC source: 0001725160-21-000190 · wf-form4_163062551581670.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,297,342 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $68.53 to $68.59. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 23:32 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 13,482 | $67.82 | $914,330.37 |
DisclosureSEC source: 0001725160-21-000190 · wf-form4_163062551581670.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,298,167 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $67.43 to $68.42. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| September 01, 2021 Filed Sep 2, 2021 23:32 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 12,487 | $67.09 | $837,805.28 |
DisclosureSEC source: 0001725160-21-000190 · wf-form4_163062551581670.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,311,649 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $66.41 to $67.40. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 00:01 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 607 | $51.36 | $31,173.27 |
DisclosureSEC source: 0001725160-21-000176 · wf-form4_162803520388448.xml · nonDerivative · entry 7 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,324,136 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F8 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.31 to $51.39. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 00:01 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,659 | $50.70 | $236,229.94 |
DisclosureSEC source: 0001725160-21-000176 · wf-form4_162803520388448.xml · nonDerivative · entry 6 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,324,743 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.30 to $51.25. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 03, 2021 Filed Aug 4, 2021 00:01 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,513 | $50.01 | $125,686.44 |
DisclosureSEC source: 0001725160-21-000176 · wf-form4_162803520388448.xml · nonDerivative · entry 5 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,329,402 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.30 to $50.28. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 00:01 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 927 | $53.14 | $49,264.58 |
DisclosureSEC source: 0001725160-21-000176 · wf-form4_162803520388448.xml · nonDerivative · entry 4 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,331,915 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.78 to $53.37. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 00:01 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,006 | $52.29 | $104,887.92 |
DisclosureSEC source: 0001725160-21-000176 · wf-form4_162803520388448.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,332,842 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.75 to $52.72. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 00:01 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 9,182 | $51.30 | $471,022.83 |
DisclosureSEC source: 0001725160-21-000176 · wf-form4_162803520388448.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,334,848 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.73 to $51.67. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 02, 2021 Filed Aug 4, 2021 00:01 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 6,900 | $50.01 | $345,071.76 |
DisclosureSEC source: 0001725160-21-000176 · wf-form4_162803520388448.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,344,030 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.57 to $50.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 20:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,940 | $47.76 | $283,709.84 |
DisclosureSEC source: 0001725160-21-000170 · wf-form4_162577775558750.xml · nonDerivative · entry 6 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,350,930 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $47.56 to $48.00. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 20:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 7,265 | $47.28 | $343,489.93 |
DisclosureSEC source: 0001725160-21-000170 · wf-form4_162577775558750.xml · nonDerivative · entry 5 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,356,870 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $46.55 to $47.54. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 07, 2021 Filed Jul 8, 2021 20:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 4,599 | $46.08 | $211,914.56 |
DisclosureSEC source: 0001725160-21-000170 · wf-form4_162577775558750.xml · nonDerivative · entry 4 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,364,135 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $45.52 to $46.50. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 20:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 377 | $48.83 | $18,410.46 |
DisclosureSEC source: 0001725160-21-000170 · wf-form4_162577775558750.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,368,734 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $48.11 to $49.01. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 20:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,320 | $47.17 | $250,927.38 |
DisclosureSEC source: 0001725160-21-000170 · wf-form4_162577775558750.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,369,111 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $47.08 to $48.07. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 06, 2021 Filed Jul 8, 2021 20:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 19,348 | $46.78 | $905,149.74 |
DisclosureSEC source: 0001725160-21-000170 · wf-form4_162577775558750.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,374,431 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $46.08 to $47.06. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 7, 2021 00:00 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 900 | $53.20 | $47,883.51 |
DisclosureSEC source: 0001725160-21-000162 · wf-form4_162561601212116.xml · nonDerivative · entry 4 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,393,779 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.09 to $53.43. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 7, 2021 00:00 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,180 | $52.20 | $270,371.14 |
DisclosureSEC source: 0001725160-21-000162 · wf-form4_162561601212116.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,394,679 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $51.78 to $52.75. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 7, 2021 00:00 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 13,365 | $51.27 | $685,267.65 |
DisclosureSEC source: 0001725160-21-000162 · wf-form4_162561601212116.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,399,859 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $50.69 to $51.65. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| July 01, 2021 Filed Jul 7, 2021 00:00 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 7,349 | $50.17 | $368,712.56 |
DisclosureSEC source: 0001725160-21-000162 · wf-form4_162561601212116.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,413,224 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $49.61 to $50.56. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 00:26 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,918 | $54.72 | $159,666.83 |
DisclosureSEC source: 0001725160-21-000134 · wf-form4_162267993674438.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,420,573 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $54.44 to $55.36. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 01, 2021 Filed Jun 3, 2021 00:26 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 23,876 | $53.95 | $1,288,012.31 |
DisclosureSEC source: 0001725160-21-000134 · wf-form4_162267993674438.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,423,491 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $53.44 to $54.43. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:27 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 16,823 | $60.07 | $1,010,510.51 |
DisclosureSEC source: 0001725160-21-000121 · wf-form4_162024645809800.xml · nonDerivative · entry 6 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,447,367 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F5 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $59.71 to $60.45. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:27 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,200 | $59.37 | $130,604.76 |
DisclosureSEC source: 0001725160-21-000121 · wf-form4_162024645809800.xml · nonDerivative · entry 5 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,464,190 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $58.70 to $59.68. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:27 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 5,182 | $58.03 | $300,706.80 |
DisclosureSEC source: 0001725160-21-000121 · wf-form4_162024645809800.xml · nonDerivative · entry 4 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,466,390 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $57.54 to $58.51. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:27 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,589 | $57.04 | $147,683.55 |
DisclosureSEC source: 0001725160-21-000121 · wf-form4_162024645809800.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,471,572 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $56.54 to $57.53. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 21, 2021 Filed May 5, 2021 20:27 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 228,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000121 · wf-form4_162024645809800.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 228,650 Read SEC document |
| April 21, 2021 Filed May 5, 2021 20:27 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GiftCommon Stock | 228,650 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000121 · wf-form4_162024645809800.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,474,161 Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 21:40 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 224 | $45.06 | $10,093.57 |
DisclosureSEC source: 0001725160-21-000088 · wf-form4_161774514967821.xml · nonDerivative · entry 6 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,702,811 F5 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F8 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $44.87 to $45.11. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 21:40 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 400 | $44.21 | $17,685.92 |
DisclosureSEC source: 0001725160-21-000088 · wf-form4_161774514967821.xml · nonDerivative · entry 5 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,703,035 F5 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F7 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $43.87 to $44.74. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 21:40 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 37,144 | $43.37 | $1,610,775.56 |
DisclosureSEC source: 0001725160-21-000088 · wf-form4_161774514967821.xml · nonDerivative · entry 4 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,703,435 F5 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading arrangement adopted by the Reporting Person. Shares sold to satisfy withholding tax obligations upon the vesting of restricted stock units. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $42.87 to $43.78. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 21:40 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 600 | $45.06 | $27,033.48 |
DisclosureSEC source: 0001725160-21-000088 · wf-form4_161774514967821.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,740,579 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $44.99 to $45.11. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 21:40 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 2,300 | $44.25 | $101,772.93 |
DisclosureSEC source: 0001725160-21-000088 · wf-form4_161774514967821.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,741,179 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $43.88 to $44.87. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| April 05, 2021 Filed Apr 6, 2021 21:40 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 23,894 | $43.38 | $1,036,438.09 |
DisclosureSEC source: 0001725160-21-000088 · wf-form4_161774514967821.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,743,479 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $42.87 to $43.84. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 19,195 | $41.92 | $804,700.47 |
DisclosureSEC source: 0001725160-21-000052 · wf-form4_161480738876736.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,767,373 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. Read SEC document |
| March 01, 2021 Filed Mar 3, 2021 21:37 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 7,599 | $41.13 | $312,524.07 |
DisclosureSEC source: 0001725160-21-000052 · wf-form4_161480738876736.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,786,568 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 00:02 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantStock Option (Right to Buy) · Derivative | 131,250 | $0.00 Strike: $38.76 | $0.00 |
DisclosureSEC source: 0001725160-21-000038 · wf-form4_161352010527706.xml · derivative · entry 4 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,250 Underlying: Common Stock · 131,250 shares Expires 2031-02-10 F3 · derivative.exercise_date: The option vests and becomes exercisable in 48 substantially equal monthly installments following the grant date. Read SEC document |
| February 11, 2021 Filed Feb 17, 2021 00:02 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | GrantCommon Stock | 43,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001725160-21-000038 · wf-form4_161352010527706.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,794,167 F1 · shares: Represents restricted stock units, each of which represent a contingent right to receive one share of common stock, and which will vest in substantially equal annual installments over a four year period following the grant date. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 1,300 | $38.54 | $50,107.98 |
DisclosureSEC source: 0001725160-21-000023 · wf-form4_161239298598585.xml · nonDerivative · entry 3 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,750,417 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F4 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $38.50 to $38.55. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 12,417 | $37.68 | $467,844.00 |
DisclosureSEC source: 0001725160-21-000023 · wf-form4_161239298598585.xml · nonDerivative · entry 2 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,751,717 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F3 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $37.50 to $38.10. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 3, 2021 22:56 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 13,077 | $37.23 | $486,885.48 |
DisclosureSEC source: 0001725160-21-000023 · wf-form4_161239298598585.xml · nonDerivative · entry 1 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,764,134 F1 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F2 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $36.50 to $37.49. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| January 04, 2021 Filed Jan 7, 2021 01:25 UTC | Zentalis Pharmaceuticals, Inc. ZNTL · Entity 5772 | SaleCommon Stock | 6,813 | $53.06 | $361,519.58 |
DisclosureSEC source: 0001725160-21-000008 · wf-form4_160998272301109.xml · nonDerivative · entry 6 SUN ANTHONY Y · CIK 0001377952 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,777,211 F2 · kind: The sale reported in the Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 22, 2020. F6 · price: The price reported is a weighted average price. The shares were sold in multiple transactions at per share prices ranging from $52.85 to $53.74. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer, or any stockholder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.